Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16652185 | 1.00 | CACNA1G (0.35) | CACNA1GCACNA1HCACNA1ICYP19A1HCRTR1 | |
| SCHEMBL22479923 | 0.83 | CACNA1G (0.35) | CACNA1GCACNA1HCACNA1ICYP19A1HCRTR1 | |
| SCHEMBL1305945 | 0.81 | HCRTR2 (0.42) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL7254156 | 0.81 | ESR2 (0.41) | CACNA1GCACNA1HCACNA1ICYP19A1HCRTR1 | |
| SCHEMBL19432763 | 0.81 | CACNA1G (0.35) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL17476831 | 0.81 | HCRTR2 (0.42) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL1305947 | 0.81 | HCRTR2 (0.42) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL7787343 | 0.81 | TSHR (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL16377614 | 0.81 | TSHR (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL5371551 | 0.81 | TSHR (0.50) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884861-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-9334263-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2015058129-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, PRKACA, CKMT1A; CKMT1B | CACNA1G 4272/4885CACNA1H 4552/4885CACNA1I 4586/4885 |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, PRKACA, CKMT1A; CKMT1B | CACNA1G 4272/4885CACNA1H 4552/4885CACNA1I 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.